Market Overview

Safe Bulkers The Best Play For A Dry Bulk Recovery, Says Morgan Stanley

Share:
Safe Bulkers The Best Play For A Dry Bulk Recovery, Says Morgan Stanley

With the dry bulk market gradually showing signs of a recovery, Morgan Stanley’s Fotis Giannakoulis believes Safe Bulkers, Inc. (NYSE: SB) is the best play in the dry bulk segment, given its “positive operating cash flow, ample liquidity and minimal dilution risk.”

Giannakoulis maintains an Equal-Weight rating on the company, while raising the price target from $1.10 to $1.20.

2Q Performance

Safe Bulkers reported its 2Q results marginally above expectations, with the EPS of $(0.14) beating the consensus and the estimate.

Daily revenues came in at $7.6kpd, in line with the estimate, while expenses were 3 percent below expectations, leading to higher than expected EBITDA of $8.9 million.

“In 2Q, SB took delivery of the Kypros Spirit, a Panamax bulker, bringing the company's total fleet to 37 vessels. Four newbuilds are still expected for delivery; three in 2017 and one in 2018,” Giannakoulis mentioned.

Related Link: Credit Suisse On Safe Bulkers: "Not Getting Any Better"

The analyst believes that the remaining capex, worth $100 million, can be covered through the company’s existing liquidity of $170 million, and management has indicated that there was no intention of taking on any additional debt.

Liquidity Position

Giannakoulis also pointed out that dilution was unlikely, given that the operating cash flow was already positive, with Safe Bulkers having sufficient liquidity to see it through the current downturn.

According to the Morgan Stanley report, “Management was firm that they have sufficient cash and that they intend to do whatever it takes to avoid issuing any equity, suggesting that in the event of a further market deterioration the disposal of the newbuilds could be the alternative if necessary.”

During the previous quarter, the company had taken on a series of refinancings of its debt facilities, bringing its cash breakeven to lower than $8kpd.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for SB

DateFirmActionFromTo
Nov 2018UpgradesHoldBuy
Oct 2018UpgradesIn-LineOutperform
Jul 2018UpgradesNeutralBuy

View More Analyst Ratings for SB
View the Latest Analyst Ratings

Posted-In: dry bulk Fotis GiannakoulisAnalyst Color Price Target Commodities Reiteration Markets Analyst Ratings Best of Benzinga

 

Related Articles (SB)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Jefferies Ponders Whether Gilead Sciences Should Experiment With An HCV Spinoff

Benzinga's Top Downgrades